NEW: Updates on Midbrain Organoid technology.

ODISEI Oncology

Cancer Organoid Based Drug Efficacy Testing Service
The oncology drug efficacy evaluation platform is based on patient-derived organoids (PDOs). This advanced platform enables the evaluation of oncology agents and immunotherapeutics by utilizing a co-culture system incorporating immune cells from the tumor microenvironment.

Next-Generation Anti-Cancer Drug Development & Efficacy Evaluation with Patient-Derived Organoids (PDOs)

We specialize in cutting-edge organoid-based solutions, delivering exceptional services to the pharmaceutical and biotechnology industries. Comprehensive support is provided for pre-clinical research and drug development, ensuring innovative and reliable outcomes.
By leveraging advanced mimicking capabilities and diverse tissue sources, these organoid based platforms offer researchers deeper insights into drug efficacy and safety.
These solutions streamline the transition from discovery to development, enhancing predictability and increasing clinical success rates.

High-Fidelity Preclinical Models

ODISEI-ONC utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.
These models preserve the original tumorís genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.

Extensive Organoid Biobanking

A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.

Available pre-clinical research

  • Donor-matched immune microenvironment
  • Various patient-derived organoid lineups
  • High-resolution data (HCS, FACS, NGS, scRNAseq, multiflex IHC)
  • Fully customized service

Available clinical data

  • Basic clinical data
  • Drug sensitivity prediction
  • Patient follow-up data
  • Clinical bioinformatics (NGS, RNAseq, Spatial biology)

Validation Complete for caner organoid

  • Clinical information
  • Drug sensitivity test
  • Genetic mutation (WES analysis)
  • Specific cancer marker expression
    (Immunohistochemistry, Multiflex)

WES analysis in pancreatic cancer organoid

WES analysis in pancreatic cancer organoid

Enhance clinical predictive accuracy by developing advanced models that more accurately recapitulate the Tumor Microenvironment (TME)

Immune-Microenvironment with Cytotoxic T cells

Immune checkpoint determine whether cancer cells are killed after TCR-MHC binding
Establishment of an immune checkpoint blockade evaluation platform utilizing cancer organoids and autologous T cells

Organoid T cell interaction

Killing effect

Tumor-Infiltrating Lymphocyte (TIL)

Regulatory T cell (Treg)

Macrophage

Cancer Associate Fibroblast (CAF)

Cancer Organoid

Breast Cancer

Organism: Human
Product type: Tissue derived organoid
Tissue: Breast
Disease: Breast cancer

Cholangiocarcinoma

Organism: Human
Product type: Tissue derived organoid
Tissue: Bile duct
Disease: Cholangiocarcinoma

Colorectal Cancer

Organism: Human
Product type: Tissue derived organoid
Tissue: Intestine (Colon)
Disease: Colorectal cancer

Pancreatic Cancer

Organism: Human
Product type: Tissue derived organoid
Tissue: Pancreas
Disease: Pancreatic cancer

Gastric Cancer

Organism: Human
Product type: Tissue derived organoid
Tissue: Stomach (Gastric)
Disease: Gastric Cancer, Malignant ascites

Ovarian Cancer

Organism: Human
Product type: Tissue derived organoid
Tissue: Ovary
Disease: Ovarian Cancer

Lung Cancer

Organism: Human
Product type: Tissue derived organoid
Tissue: Lung
Disease: NSCLC (Non-small cell lung cancer)

Endometrial Cancer

Organism: Human
Product type: Tissue derived organoid
Tissue: Endometrium
Disease: Endometrial cancer

Real-World Application Feedbacks

CASE STUDY

With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have been adopted. However, many of these approaches have limitations in replicating the complexity of human skin physiology. The emergence of skin organoids has provided a breakthrough, enabling more accurate and diverse efficacy evaluations, particularly in areas such as hair growth,...

Read on
Professor Lee Chang-seok Eulji University
CASE STUDY

Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without the need for any labeling, offering a clear advantage in live-cell imaging. To validate this capability, we conducted an organoid-based analysis using intestinal organoids. Among various organoid types, intestinal organoids are known to closely replicate the functional structure of the...

Read on
Tomocube (Spatial)
CASE STUDY

Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but also the spatial distribution, density, and proximity between proteins. While this approach is already widely adopted in international research, it remains relatively underutilized in Korea, making it challenging to apply in domestic studies. Thanks to Lambda Biologics, which became the...

Read on
Seoul National University College of Medicine
CASE STUDY

Among the many fermented foods we consume, kimchi is particularly known for containing a diverse range of lactic acid bacteria, which are believed to influence the activation of immune cells in the body. In our research institute, we successfully isolated a bacterial strain that appears to enhance immune cell function. To evaluate its effect in the intestinal environment, we utilized the ODISEI-Gut platform. Using this platform, we investigated how the...

Read on
K Research Institute
CASE STUDY

We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of clinical samples posed a consistent challenge. By utilizing Lambda Biologics’ Multiplex Marker Analysis service, we were able to detect the expression of 31 markers on a single slide, enabling more comprehensive analysis while conserving precious tissue samples. This significantly enhanced...

Read on
Bundang Jesaeng General Hospital
CASE STUDY

Gastric cancer is one of the leading causes of cancer-related mortality worldwide. It is a malignant solid tumor characterized by poor prognosis due to difficulties in early diagnosis and its rapid progression. Unlike many other solid tumors that primarily metastasize via lymphatic or hematogenous routes, gastric cancer most commonly spreads through the peritoneum. Peritoneal metastasis is associated with particularly poor outcomes and marked resistance to treatment, highlighting the urgent need...

Read on
SOON CHUN HYANG UNIVERSITY HOSPITAL
CASE STUDY

Breast cancer is one of the most commonly diagnosed cancers among women worldwide. It is a complex and heterogeneous disease, with its progression and treatment response varying significantly depending on factors such as hormone receptor status, HER2 expression, and genetic background. Breast cancer is typically classified based on the expression of three major biomarkers: estrogen receptors (ER), progesterone receptors (PR), and HER2. Among these, tumors that do not express any...

Read on
GANGNAM SEVERANCE HOSPITAL
CASE STUDY

Gastric cancer is one of the leading causes of cancer-related mortality worldwide. It is a malignant solid tumor characterized by poor prognosis due to difficulties in early diagnosis and its rapid progression. Unlike many other solid tumors that primarily metastasize via lymphatic or hematogenous routes, gastric cancer most commonly spreads through the peritoneum. Peritoneal metastasis is associated with particularly poor outcomes and marked resistance to treatment, highlighting the urgent need...

Read on
SOON CHUN HYANG UNIVERSITY HOSPITAL
CASE STUDY

Our newly developed drug differs from previously known therapeutics in that it directly penetrates various tumor tissues to exert its efficacy. Therefore, it was essential to analyze the drug’s penetration within the tumor microenvironment. To evaluate this, we conducted permeability testing in a co-culture system of tumor organoids and cancer-associated fibroblasts (CAF). This approach allowed us to determine the optimal drug concentration required for effective therapeutic action. As a result,...

Read on
Autotelic bio
CASE STUDY

We have been developing products utilizing various bacterial strains and have explored multiple methods to evaluate the efficacy of our developed strains. However, due to the nature of obligate anaerobic bacteria, there were significant limitations in applying conventional in vitro efficacy evaluation methods. To overcome these challenges, we explored different testing approaches and discovered the ODISEI platform. Through this platform, we confirmed that organoids enable the effective analysis of obligate...

Read on
Chong Kun Dang - better life through better medicine
CASE STUDY

Cholangiocarcinoma is a cancer with no distinct early symptoms, making early detection challenging, and its exact pathogenesis remains unclear. In Western countries, it is classified as a rare cancer due to its relatively low incidence, and its symptoms vary depending on the tumor location, further complicating prevention and early diagnosis. Over the years, many clinical trials for cholangiocarcinoma treatments have faced high failure rates, resulting in a lack of globally...

Read on
SEOUL NATIONAL UNIVERSITY HOSPITAL
CASE STUDY

Pancreatic cancer is one of the most challenging malignancies to diagnose early, as it presents few or no symptoms in its initial stages. It is also known to have the lowest survival rate among all cancers. Additionally, the tumor microenvironment (TME) of pancreatic cancer poses significant barriers to drug penetration, driving the development of innovative therapeutic strategies to overcome these challenges. To better replicate the pancreatic cancer microenvironment, we conducted...

Read on
SEOUL NATIONAL UNIVERSITY HOSPITAL
CASE STUDY

Organoids overcome the limitations of traditional 2D cell culture models by enabling more physiologically relevant experiments in a 3D, multicellular environment. In particular, utilizing both tumor and normal organoids allows for rapid and precise evaluation of drug specificity, efficacy, and toxicity. Due to their structural similarity to actual tissues, organoids provide a more realistic platform for research. This makes them highly promising not only for drug development but also for...

Read on
Mount Sinai
CASE STUDY

Organoid has proven to be a powerful tool for human sample-based validation in the drug development process. In this study, CRC organoids were utilized to evaluate the efficacy of candidate drugs, demonstrating superior anticancer effects compared to conventional therapies. This highlights the predictive accuracy and practical applicability of organoid models. Moreover, by integrating organoid models with traditional 2D and PDX systems, the platform has established itself as an essential component...

Read on
Korea Advanced Institute of Science & Technology (KAIST)
CASE STUDY

The tumor organoid efficacy evaluation platform has proven to be an invaluable tool for assessing the anticancer potential of small molecules. Using CRC organoids to validate human POC based on existing 2D experimental data, we observed that the drug demonstrated superior anticancer effects compared to conventional therapies. What stood out the most was the platform’s ability to accurately evaluate patient-specific drug responses using patient-derived tissues. Additionally, it simplified the process...

Read on
Yonsei University
CASE STUDY

In Thailand, cholangiocarcinoma is a prevalent disease. While many companies have traditionally relied on 2D cell models and mouse models for drug development, these approaches often face challenges in clinical Phase 3 trials, where efficacy issues rather than toxicity lead to project discontinuation. Although organoids have not yet reached the later stages of clinical application, their ability to reflect individual patient characteristics and tumor heterogeneity offers significant potential. Our recent...

Read on
Mahidol University
CASE STUDY

Lung cancer is one of the most commonly diagnosed cancers worldwide and a leading cause of cancer-related mortality. Among its subtypes, non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of all cases and demonstrates the highest response rates in the field of immunotherapy, making it a key focus for novel drug development. However, predicting drug responsiveness has been challenging due to variability between patients. Lambda Biologics’ patient-derived organoids address...

Read on
SEOUL NATIONAL UNIVERSITY HOSPITAL
CASE STUDY

The virus platform has proven its innovative potential in developing infection models using organoids. It significantly accelerated the development of antiviral drugs and enabled precise drug evaluation in a human-like environment, which was highly impressive. Avion Research Institute achieved excellent results in efficacy validation during the drug development process using this platform....

Read on
ABION BIO
CASE STUDY

As an expert with 20 years of experience in novel drug development, I firmly believe that tumor organoids are an innovative technology enabling accurate evaluation by comparing patient-derived cancer and normal cells. They offer significantly higher precision in drug assessment than traditional cell and animal models. Additionally, organoids allow the observation of patient-specific drug responses, making them invaluable for clinical trial design and biomarker development. Using organoid efficacy evaluations, I...

Read on
LigaChemBio
CASE STUDY

I have been utilizing tumor organoid technology since 2020. Recently, I’ve come to appreciate how combining organoid technology with AI can revolutionize the drug discovery process by enhancing efficiency and accelerating personalized therapy development. Notably, using tumor organoid models to validate AI-driven antibody therapy data has further clarified their effectiveness, and the outcomes from my recent studies have exceeded expectations....

Read on
ABL Bio - medicine for A Better Life
CASE STUDY

Colorectal cancer, unlike other cancer types, is significantly influenced by dietary and lifestyle factors. Evaluating drug responsiveness based on specific genetic markers and MSI (microsatellite instability) in patients is crucial, and colorectal cancer organoids were developed to address these challenges. Using the organoids, we observed that they better simulated patient diversity compared to traditional 2D cell lines and were more convenient to use than mouse xenograft models. This approach not...

Read on
Gangnam Severance Hospital
CASE STUDY

Our NK immune cell-based cancer therapy faced challenges during its development and efficacy evaluation. To address these issues, we explored various platforms and discovered the Lambda Biologics platform, which we utilized for efficacy testing. Contrary to our initial expectations, the platform provided a wealth of additional information. Beyond simply evaluating efficacy, we were able to establish optimal conditions to maximize the therapeutic potential of our NK immune cell-based therapy. Based...

Read on
CHA Medical & Bio Group
CASE STUDY

COSMAX는 글로벌 화장품 업계를 선도하며, 혁신적인 원료 개발과 제품 효능 평가에 ODISEI SKIN 플랫폼을 도입하여 놀라운 결과를 경험했습니다. 이를 통해 발모, 탈모, 새치 등 신규 화장품 원료의 잠재력을 신뢰성 있게 확인하고 기존의 한계를 뛰어넘는 발전을 이루어냈습니다. 정확한 효능 검증 ODISEI SKIN 플랫폼은 기존 평가 방법이 놓칠 수 있는 피부 생리적 반응까지 정밀하게 분석할 수 있는 도구입니다. 예를 들어, 새로운 항노화 성분에서 피부 조직의 콜라겐 생성 촉진 효과를 데이터 기반으로 입증하였으며,...

Read on
Cosmax - The Science of Korean Beauty
CASE STUDY

Human intestinal organoids can accurately mimic the structure and function of the human intestine, making them an ideal platform for studying the early stages of organ development. The KRIBB research team not only developed the platform but also utilized it to discover a new probiotic, Lactobacillus reuteri DS0384, which has shown remarkable potential in promoting gut development and preventing diseases. Notably, this innovative research has been transferred by KRIBB to...

Read on
KRIBB 손미영/Mi-Young Son
CASE STUDY

LambdaBiologics is supporting toxicity evaluation and efficacy verification for pet pharmaceutical products and functional foods through its innovative organoid platform, offering an alternative to animal testing. Platform Potential Proven Through Toxicity Evaluation of Pet Toothpaste LambdaBiologics organoid platform was recently utilized for the toxicity evaluation of a pet toothpaste product. Due to pets nature, these kind of toothpaste products are ought to be frequently ingested by animals, yet there is...

Read on
JAYU PET
CASE STUDY

LambdaBiologics provides OECD-guideline-based testing services verified under GLP standards through its innovative research platform and diverse preclinical solutions. The company ensures optimal cost efficiency and performance for its clients, supporting them in meeting submission requirements for U.S. and European regulatory agencies. LambdaBiologics offers integrated services across all stages of drug development, utilizing cutting-edge research technologies, including alternative methods to animal testing. Various alternative testing approaches, such as toxicity evaluation, are...

Read on
The Organisation for Economic Co-operation and Development | OECD
CASE STUDY

KTR established Korea's first Animal Alternative Testing Center and has built related facilities in the biopharmaceutical sector to provide an innovative research environment. Currently, toxicity evaluations required in the drug development process are conducted through alternative testing methods, with six OECD TG experiments already implemented. In addition, a variety of alternative tests are systematically operated under GLP certification. Lambda Biologics and KTR possess collaborative infrastructure across all stages of drug...

Read on
KTR (Korea Testing & Research Institute)
CASE STUDY

Holotomography is a groundbreaking technology that enables high-resolution observation of dynamic changes in cells without fluorescent staining, while preserving their natural state. This technique does not interfere with the physiological changes of cells, allowing for real-time analysis of their internal structures and functions over extended periods. LEE (SNU): "Our research team utilized holotomography to observe various dynamic changes, such as cell division, migration, and death, in mouse intestinal organoids over...

Read on
SEOUL NATIONAL UNIVERSITY

Easy request

Let us know who you are and what you’re working on – so we can better support your research journey.